Teva Pharmaceutical Industries
Recent events
Recent events tied to this brand in public sources.
Back to profile13 entries
2026
Teva reports quarterly earnings
Teva Pharmaceutical Industries released quarterly earnings data, reporting $0.86 earnings per share and revenue of $4.39 billion for the quarter.
2026
Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva received U.S. FDA approval for Weltruza, a monthly injection for the treatment of schizophrenia, as reported by Reuters.
2026
BioXcel agrees to sell assets to Teva for up to $145M
BioXcel Therapeutics agreed under an asset purchase agreement to sell substantially all its assets to Teva for $57.5 million in upfront cash plus assumption of certain liabilities, with up to an additional $67.5 million tied to its pending FDA application for at-home use of Igalmi and up to $20 million more if sales thresholds are met. Teva's offer serves as a stalking horse bid subject to court approval.
2022
Florida reaches opioid settlements with CVS Health and drug companies
Florida reached settlements totaling more than $878 million with CVS Health, Teva Pharmaceutical Industries, Allergan, and Endo International over claims concerning their roles in fueling the state's opioid epidemic. The companies denied wrongdoing in agreeing to settle.
2022
Teva reaches Texas opioid claims settlement
Teva reached a $225 million settlement to resolve Texas claims that it fueled the opioid epidemic through improper marketing of addictive pain medications. The report says Teva did not admit wrongdoing as part of the settlement.
2022
Teva settles investor price-fixing lawsuit
Teva settled a US investor class action over alleged price fixing, agreeing to pay $420 million without admitting wrongdoing. Teva denied the claims; the lawsuit followed an investigation by US authorities into alleged price fixing in the generic drugs industry.
2022
Teva agrees to $420 million shareholder litigation settlement
Teva agreed to pay $420 million to settle shareholder litigation alleging that it concealed an anti-competitive scheme to fix generic drug prices. Teva did not admit wrongdoing, and the agreement requires approval by the judge overseeing the case.
2021
Teva upsizes and prices sustainability-linked notes offering
Teva announced that it had increased the size of its sustainability-linked senior notes offering and priced approximately $5 billion equivalent of notes. The offering proceeds are intended primarily to repay existing debt.
2021
Bioeq and Teva enter commercialization agreement for ranibizumab biosimilar
Bioeq, a joint venture company of Polpharma Biologics Group and Santo Holding, concluded a commercial partnership with Teva for its ranibizumab biosimilar candidate in Europe, Canada, Israel and New Zealand.
2021
Mylan sues Teva over alleged Copaxone competition restraints
Mylan Pharmaceuticals filed a federal lawsuit against Teva, alleging that Teva used tactics to delay competition for its multiple sclerosis drug Copaxone. The allegations are not presented as a court determination, and Teva had not yet responded.
2020
EU fines Teva over generic modafinil delay agreement
The European Union fined Teva after the European Commission said Teva breached EU antitrust rules by agreeing with Cephalon to keep a cheaper generic modafinil drug off the market.
2020
U.S. government sues Teva over alleged Copaxone kickbacks
The U.S. Department of Justice sued Teva under the Federal False Claims Act. The lawsuit alleges that Teva companies used purportedly independent foundations to pay Medicare co-pays for Copaxone patients in violation of the Anti-Kickback Statute; the allegations are not presented as a court finding.
2019
Eurolife completes acquisition of Teva's Hungarian IV infusion business
Eurolife Healthcare said it completed the acquisition of Teva Pharmaceutical Industries' intravenous infusion business in Hungary.